Marker Therapeutics, Inc.
MRKR
$1.21
-$0.07-5.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -48.07% | 32.79% | |||
| Gross Profit | 48.07% | -174.02% | |||
| SG&A Expenses | -6.96% | 45.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -35.66% | 36.32% | |||
| Operating Income | 35.66% | -116.16% | |||
| Income Before Tax | 42.56% | -85.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 42.56% | -86.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 42.56% | -86.67% | |||
| EBIT | 35.66% | -116.16% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 42.53% | -87.05% | |||
| Normalized Basic EPS | 42.57% | -85.41% | |||
| EPS Diluted | 42.53% | -87.05% | |||
| Normalized Diluted EPS | 42.57% | -85.41% | |||
| Average Basic Shares Outstanding | 0.00% | -0.23% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||